NCT00279734View on ClinicalTrials.gov

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tetanus + pnemococcal vaccines alone

0 mg + vaccines, Single dose, 28 days.

DRUG

Abatacept + vaccines

Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.

DRUG

Abatacept + vaccines

Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.

DRUG

Abatacept + Vaccines

parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.

Trial Locations (3)

Unknown

Qutintiles Phase I Services, Lenexa

Parexel International Corp, Baltimore

PPD Development, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00279734 - Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers | Biotech Hunter | Biotech Hunter